logo
NasdaqGS:ONC logo

BeiGene Community

NasdaqGS:ONC Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

ONC logo
BeiGene
AN
AnalystConsensusTarget
Consensus Narrative from 23 Analysts

US Facility And Phase III Trials Will Expand Markets

Key Takeaways Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies. Investment in R&D and successful product trials could enhance margins and foster long-term growth in revenues and pipeline value.
View narrative
US$330.97
FV
22.8% undervalued intrinsic discount
23.45%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
1 day ago author updated this narrative